AyuVis is a start-up biopharmaceutical company, developing a new class of immunotherapies to prevent and treat inflammation and infection.
AyuVis has raised $2.1M in total funding. The most recent round was Grant. The last funding was announced in May 2023.
AyuVis's investors include National Heart, Lung and Blood Institute, The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
AyuVis is headquartered in Fort Worth, United States.
AyuVis is a start-up biopharmaceutical company, developing a new class of immunotherapies to prevent and treat inflammation and infection.
AyuVis is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"AyuVis — Funding & Investors." VCBacked, May 15, 2023, https://www.vcbacked.co/company/ayuvis. Accessed November 11, 2026.
VCBacked. (2023). AyuVis — Funding & Investors. Retrieved November 11, 2026, from https://www.vcbacked.co/company/ayuvis
{{cite web |title=AyuVis — Funding & Investors |url=https://www.vcbacked.co/company/ayuvis |website=VCBacked |access-date=November 11, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at AyuVis? Request a listing update